FDA approves $56,000 treatment for Alzheimer’s with Questionable Efficacy – What happens Next?
Co-hosted by the Hopkins Business of Health Initiative (HBHI) and the Hopkins Economics of Alzheimer’s Disease and Services Center (HEADS Center)
Friday, July 23, 2021
This symposium is just the start of an ongoing and important conversation. We hope you continue to follow the latest on aducanumab, as well as the most important health policy current events by:
- Following the Hopkins Business of Health Initiative on Twitter or signing up for their mailing list here.
- Following the Hopkins Economics of Alzheimer’s Disease and Services Center on Twitter or reach out here.
- Following Tradeoffs on Twitter, signing up for their weekly newsletter highlighting new health policy research or subscribing to the podcast.
On June 7, 2021 the FDA approved a new treatment for Alzheimer’s, yet there remains a contentious debate about whether the drug is effective. While this debate rages, millions of people may be eligible for this drug costing $56,000/year which, in one stroke, might double the nation’s spending on prescription drugs. What happens next? The Hopkins Business of Health Initiative and the Hopkins Economics of Alzheimer’s Disease and Services Center have assembled experts to lay the groundwork to inform action steps that would best leverage the opportunities and limit the challenges tied to the approval of aducanumab.
Dan Polsky, PhD, Bloomberg Distinguished Professor of Health Policy and Economics, Director, Hopkins Business of Health Initiative, Co-Director, Hopkins Economics of Alzheimer’s Disease and Services Center
Dan Gorenstein, Executive Producer and Host of Tradeoffs
Panel 1 at 9:00 AM EST
Accelerated approval of Aducanumab by FDA – scientific justification and implications of approval for patients
Caleb Alexander, MD, Professor of Epidemiology, Johns Hopkins University
Marwan Noel Sabbagh, MD, FAAN, CCRI, Director of Translational Research, Cleveland Clinic Lou Ruvo Center for Brain Health
Holly Fernandez Lynch, JD, MBe John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, Assistant Professor of Law, University of Pennsylvania
Panel 2 at 10:00 AM EST
Market access to aducanumab – the clinical issues and dilemmas
Halima Amjad, MD, MPH, Assistant Professor of Medicine, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine
Michael Atkinson, Vice President MedPro Associates, Husband of Patient
Alice Bonner, Director of Strategic Partnerships for CAPABLE, Johns Hopkins University. Former Secretary of the Executive Office of Elder Affairs for the Commonwealth of Massachusetts
Panel 3 at 11:00 AM EST
Who pays and how – consideration of options for Medicare
Tricia Neuman, Sc.D, Senior Vice President, Kaiser Family Foundation and Executive Director of Program on Medicare Policy
Sean Tunis, MD, MSc, Senior Fellow, Center for Evaluation of Value and Risk in Health, Tufts Medical Center, Mentor-in-Residence, Johns Hopkins Tech Ventures
Howard Fillit, MD, Founding Executive Director and Chief Science Officer, The Alzheimer’s Drug Discovery Foundation, Clinical Professor of Geriatric Medicine, Palliative Care and Neuroscience, The Icahn School of Medicine at Mount Sinai
Joshua Sharfstein, MD, Vice Dean for Public Health Practice and Community Engagement, Professor of the Practice, Bloomberg School of Public Health